Follow-on Prompt:
Protagonist Therapeutics is a company that has developed a technology to delivery at least one type of peptide via oral pill. Is their technology generally considered by experts to be a technology that could be broadly applicable to delivering many different types of peptides via oral pill? If not, are there other biotech companies out there that do seem to have developed a “Platform technology” that could be more widely applicable to other peptides, to make them orally deliverable by pill? If so, identify and link to their websites.
Claude Opus 5.5 Response:
Short answer: no, not as a delivery technology. Protagonist’s platform is broadly useful, but it is useful for discovering new drugs. It is not a way to take an existing peptide and make it work as a pill.
Companies with carrier-style platforms
These technologies are meant to be applied to many existing peptides. There are three main types, and none of them is universal. Chemical enhancers typically give low single-digit bioavailability with high variability. They also need a lot of drug and fasting dosing, so they work best for potent peptides with long half-lives. Device approaches get much higher bioavailability but have less long-term human data.
Chemical permeation enhancers (the clinically proven approach)
-
Novo Nordisk (Eligen/SNAC, originally from Emisphere): used in Rybelsus and oral Wegovy. This is the most validated oral peptide platform in the world, but it is proprietary to Novo. novonordisk.com
-
Chiasma’s TPE technology (Mycapssa, now owned by Chiesi): the octreotide capsule (Mycapssa®), developed through Chiasma’s Transient Permeation Enhancer (TPE) technology, also received FDA approval in 2020 for the treatment of acromegaly. mycapssa.com
-
Entera Bio (N-Tab): probably the clearest independent example of a multi-peptide platform. Its lead is oral PTH(1-34) for osteoporosis, and with OPKO it has applied N-Tab to LA-PTH, GLP-1/Glucagon and GLP-2 targets. enterabio.com
-
Enteris BioPharma (Peptelligence): an enteric-coated tablet with an enhancer, used across several partnered peptides and licensed out to other companies. enterisbiopharma.com
Ingestible devices (highest bioavailability, earlier stage)
-
Rani Therapeutics (RaniPill): a robotic capsule that injects drug into the intestinal wall. In its obesity program, the pill achieved bioavailability greater than 150% versus matched subcutaneous PG-102. This is still Phase 1, and repeat-dose data in patients is expected in 2027. ranitherapeutics.com
-
Biograil (BIONDD): a Danish company whose platform device contained within a standard-size oral capsule that mechanically delivers active therapeutic macromolecules into the stomach mucosal wall. It is preclinical or early clinical. biograil.com
Formulation discovery engines
-
Vivtex: an MIT spin-out that uses high-throughput GI tissue screening and AI to find the right formulation for each molecule. Novo licensed it in February 2026 in a deal totaling up to $2.1 billion, which is a strong signal that big pharma sees it as broadly applicable. vivtex.com
A cautionary example is Oramed (POD platform). Its oral insulin failed Phase 3 in 2023, which shows that “platform” claims don’t always survive large trials.
Bottom line: For true peptide-agnostic delivery, the strongest candidates are SNAC (clinically proven but Novo-only), Entera’s N-Tab (multiple peptides, independent), and the device players Rani and Biograil (best bioavailability, least mature). Protagonist and Merck are the leading examples of the other strategy: redesign the peptide itself so it doesn’t need much help. For your biohacker readers, it’s worth noting that none of these technologies are behind the “oral BPC-157” capsules sold online.
Sources:
Follow-on Prompt:
Is there any scientific or clinical evidence that the oral BPC-157" capsules sold online actually work and delivery the peptide successfully for clinical effectiveness?
Short answer: no. No published data shows that swallowed BPC-157 reaches the bloodstream in humans, and no controlled trial shows it works clinically by any route. There is one plausible case: a local effect inside the gut. Here is what the evidence does and doesn’t cover.
1. Delivery: has anyone shown it gets absorbed?
No. The marketing depends on one real finding: BPC-157 was isolated from gastric juice and is described as unusually stable there. Stability in the stomach is only the first step, though. The peptide still has to cross the intestinal wall. The one formal pharmacokinetic study, in rats and dogs, measured only injected doses. It found intramuscular bioavailability of roughly 14–19% in rats and 45–51% in dogs, and a plasma half-life under 30 minutes. It had no oral arm. As of this year, no peer-reviewed study in any species has measured blood levels after a swallowed dose.
Basic pharmacology also works against it. BPC-157 is a hydrophilic 15-amino-acid peptide (~1.4 kDa). As in my last answer, peptides like this normally get well under 1% oral bioavailability. Semaglutide, a far more engineered molecule, reaches only about 1% even with Novo’s SNAC enhancer. Most BPC-157 capsules use no enhancer at all, or at most an enteric or delayed-release coating, which protects the peptide from stomach acid but doesn’t help it cross the gut wall.
2. Efficacy: does it work?
Animals: The oral data is mostly rats given BPC-157 in drinking water or by gavage. Most of it comes from one laboratory: Predrag Sikirić’s group at the University of Zagreb. That lab reports striking effects across a huge range of tissues, but independent replication is thin. The strongest oral signal is local, meaning protection of the stomach and intestinal lining in models of ulcers, colitis and NSAID damage.
Humans: As of April 2026, no published, peer-reviewed randomized controlled trial of BPC-157 exists in humans for any indication. A 2025 systematic review screened 544 articles and found one eligible human study. The whole human evidence base is under 30 people across three uncontrolled pilot reports, none using oral dosing. Croatia’s ulcerative colitis Phase II program was never published as a standalone trial.
The one oral human dataset comes from a vendor, OvationLab. It was an open-label study of 500 mcg delayed-release capsules taken twice daily, with patient-reported improvements in pain. It had no placebo arm, no blinding and no blood measurements, and it comes from a company that sells the product. Pain scores are also exactly the outcome where placebo effects are largest.